Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fulvestrant + 177Lu-DOTATATE
- Development stage
- Unknown
- Lead developer
- University of Chicago Comprehensive Cancer Center
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intramuscular, Intravenous
01
Overview
fulvestrant + 177Lu-DOTATATE is a combination therapy being investigated for the treatment of advanced pancreatic neuroendocrine tumors (pNETs). The regimen consists of fulvestrant, a selective estrogen receptor degrader (SERD) that binds to and promotes the degradation of estrogen receptors, and 177Lu-DOTATATE, a radiolabeled somatostatin analog. 177Lu-DOTATATE functions as a peptide receptor radionuclide therapy (PRRT), specifically targeting somatostatin receptors (primarily SSTR2) overexpressed on the surface of neuroendocrine tumor cells to deliver cytotoxic beta radiation from the Lutetium-177 isotope directly to the cancer cells. This combination, evaluated in clinical trials led by the University of Chicago, explores the potential for hormonal modulation to enhance the therapeutic profile of PRRT in patients with advanced pNETs.
- Other names
- Fulvestrant and 177Lu-DOTATATE177Lu-DOTA-TATE and FulvestrantFulvestrant + Lutathera
02
Targets
SSTR2 (Somatostatin receptor type 2)ER (Estrogen receptor)
Beyond the preview
Go deeper on fulvestrant + 177Lu-DOTATATE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fulvestrant + 177Lu-DOTATATE.